Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New news soon!!!!
View:
Post by Legit62 on Mar 04, 2022 3:15pm

New news soon!!!!

Got through to customer service today and  asked about news , basically she said it would be soon!!!!! no other details,wouldnt give out any info other than soon. she said lots of calls from investors.
Comment by ggrellette on Mar 04, 2022 3:23pm
Not surprised at all that investors are calling asking about news because they believe news should be here already not soon come. Soon come to me means they are not sure when themselves. So what changed during these trials that would have caused further delays in results.
Comment by Vikingstock on Mar 04, 2022 3:35pm
As discussed below, time to eliminate this notion of a qtr report and release news whenever relevant for public release. The patient study timings and release of data is not in there hands, and would not match a qtr format without delays.
Comment by Oilminerdeluxe on Mar 04, 2022 3:39pm
No Friday after the close release, please. I have had enough of those in my life. 
Comment by Yajne on Mar 04, 2022 9:33pm
Absolutely agree Oilminerdeluxe...I've had more than my share of late Friday releases on other Co's as well, usually not pretty. That didn't happen today, so looking forward to the next week or two for BTD/AA worthy clinical data to be released. Am also hopeful that any NR delay has been in effort to include all relevant clinical data to this point. 
Comment by Oilminerdeluxe on Mar 05, 2022 12:45am
Yes Yajne. I was happy to wake up this morning and see that nothing had come in ways of news. So perhaps next week. I know I could do well with good news. Not sure what it will take to move the stock but if it's good stuff coming and not much action, the company is even cheaper for those who wish to buy. Hopefully nothing too bad. There should be quite a bit of data,  A few new 90 day and ...more  
Comment by CancerSlayer on Mar 04, 2022 10:06pm
  Yep...best to report meaningful data & material info on an "as appropriate" basis in order to avoid potentially empty, less meaningful or delayed quarterly newsletters.  Big Pharma/Biotech generally report when appropriate (I.e. larger/statistically significant data sets, Fast Track/BTD status, etc).  JMO.
Comment by floatinketucky on Mar 05, 2022 5:56am
With CA in place the release of news in not in the hands of the company.
Comment by floatinketucky on Mar 05, 2022 6:03am
Since the release of news in not in the hands of the company they probaly went to quarterly reports in a efffort to better manage news they do not control.  Data to date is being considered right now.  Signifigant data always goes through the FDA before we hear about it.  Look back to the company pr for verification.  The expectation for the BTD AA is moving closer and closer ...more  
Comment by Eoganacht on Mar 04, 2022 4:18pm
Tuesday morning would be soon...
Comment by 99942Apophis on Mar 04, 2022 4:26pm
Soon is better than in awhile. 
Comment by winr88 on Mar 04, 2022 4:34pm
This is the first newsletter for Vera. I would believe, based on my impression of her work ethic and attention to detail she will not release any newletter till the details are complete. Soon to me could be Tuesday next week or the week after.
Comment by ScienceFirst on Mar 04, 2022 5:00pm
Don't think Vera has anything to do with the newsletter.  Not her role. Clearly though, Vera is a great addition in terms of expertise in clinical trial processes but the ball is already rolling since 2019.  Sad COVID-19 has slowed the recruitment otherwise we would be much further in terms of patients treated.  Recruitment will accelerate from now on, now that we have COVID-19 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250